# Medira GmbH: Not applicable (device, behavioral) study started recruiting, 10 planned (Symptomatic Tricuspid Regurgitation (TR) Graded as Severe or Greater)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Medira GmbH |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | First-in-man Trial to Assess the Safety, Performance and Clinical Benefit of the TRICENTO G2 Transcatheter Valve System for Tricuspid Regurgitation |
| NCT ID | NCT07536724 |
| Phase | Not applicable (device, behavioral) |
| Status | recruiting |
| Conditions | Symptomatic Tricuspid Regurgitation (TR) Graded as Severe or Greater |
| Intervention types | device |
| Target enrollment | 10 |
| Site countries | Uzbekistan |
| Posted | 2026-04-17 |
| Planned start | 2026-09-29 |
| Event | Started recruiting |
| Event date | 2026-09-29 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07536724). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.